Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novavax Inc NVAX

Healthcare Biotechnology
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID... see more

Recent & Breaking News (NDAQ:NVAX)

Novavax Announces Initiation of Phase 2b/3 Hummingbird(TM) Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years

PR Newswire August 4, 2022

Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022

PR Newswire August 1, 2022

Novavax Announces Expanded Approval of Nuvaxovid(TM) COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

PR Newswire July 26, 2022

Novavax Nuvaxovid(TM) COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17

PR Newswire July 26, 2022

U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older

Canada NewsWire July 19, 2022

Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes

PR Newswire July 19, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

PR Newswire July 13, 2022

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

PR Newswire July 11, 2022

Novavax Nuvaxovid(TM) COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

PR Newswire July 5, 2022

NOVAVAX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Novavax, Inc. - NVAX

PR Newswire July 1, 2022

Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants

PR Newswire June 28, 2022

Novavax' Nuvaxovid(TM) COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over

PR Newswire June 23, 2022

Novavax COVID-19 Vaccine Nuvaxovid(TM) Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

PR Newswire June 23, 2022

NOVAVAX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Novavax, Inc. - NVAX

Business Wire June 17, 2022

Novavax COVID-19 Vaccine Nuvaxovid(TM) Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

PR Newswire June 13, 2022

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

PR Newswire June 7, 2022

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

PR Newswire May 9, 2022

Novavax to Participate in BofA Securities 2022 Healthcare Conference

PR Newswire May 4, 2022

Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022

PR Newswire May 2, 2022

FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine

PR Newswire April 29, 2022